Barinthus Biotherapeutics plc - BRNS STOCK NEWS

Barinthus Biotherapeutics announced plans to prioritize its pipeline, focusing on VTP-300 for Chronic Hepatitis B (CHB) and VTP-1000 for celiac disease, following positive interim data from ongoing Phase 2 trials. The company will restructure, reducing its workforce by 25%, and expects to extend its cash runway to Q2 2026. VTP-300 data showed significant reductions in Hepatitis B surface antigen levels, while pre-clinical data for VTP-1000 in celiac disease were promising. The Phase 1 trial for VTP-1000 is set to begin in Q3 2024, and the ongoing Phase 1 trial of VTP-850 in prostate cancer will be completed.

Barinthus Bio announced promising results from two clinical trials of its VTP-300 treatment for chronic hepatitis B (CHB). In the HBV003 trial, 67% of participants had HBsAg levels below 10 IU/mL, and 19% had undetectable HBsAg levels, with 76% becoming eligible to discontinue nucleos(t)ide analogue (NUC) therapy. Interim data from the IM-PROVE II trial, conducted with Arbutus Biopharma, showed a statistically significant difference in HBsAg levels between the VTP-300 and placebo groups 24 weeks post-treatment. VTP-300 treatment led 84% of participants to discontinue standard NUC therapy versus 53% in the placebo group. Both trials reported no serious adverse events, with the most common side effect being thyroid dysfunction. These findings suggest VTP-300's potential to be a critical component in functional cure regimens for CHB.

Barinthus Biotherapeutics (NASDAQ: BRNS) will present clinical data for its hepatitis B immunotherapy candidate, VTP-300, at the EASL Congress 2024 in Milan, Italy, from June 5-8. The presentations will include a poster on June 5 and an oral presentation on June 6. The poster will discuss how VTP-300 combined with nivolumab continues to show reductions in HBsAg levels without serious adverse events. The oral presentation will highlight that VTP-300, when administered after imdusiran, maintains lower HBV surface antigen levels and allows more subjects to discontinue NUC therapy. CEO Bill Enright expressed optimism about the potential for a functional cure for hepatitis B.

Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported its first quarter 2024 financial results highlighting progress in its T cell immunotherapy programs. The Company received FDA clearance for a Phase 1 trial in celiac disease and reported positive data from a HPV study. Barinthus also announced the appointment of a new Chief Medical Officer and upcoming milestones for 2024. Financially, the Company's cash position decreased, with no revenue in Q1 2024. Despite increased R&D expenses, the net loss decreased compared to Q1 2023.

Barinthus Biotherapeutics plc announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer. Dr. Hooftman brings over 25 years of experience in international drug development, specializing in immunology, autoimmunity, hematology, oncology, and infectious diseases. His extensive background includes successful clinical trial programs and senior management positions at leading pharmaceutical companies. Dr. Hooftman's appointment is expected to drive the development of Barinthus Bio's novel T cell immunotherapeutic candidates for chronic infectious diseases, autoimmunity, and cancer.

Barinthus Bio announced positive topline data from the Phase 1b/2 APOLLO trial of VTP-200 in persistent high-risk human papillomavirus (HPV) infections. VTP-200 demonstrated positive trends in clearance rates for both high-risk HPV and cervical lesions in groups receiving the highest ChAdOx dose. However, there was no statistically significant improvement compared to the placebo group. The trial met its primary safety endpoint, showing VTP-200 was generally well-tolerated with no severe adverse events. Future development options are being evaluated with ongoing analyses.

Barinthus Biotherapeutics plc (BRNS) reported its 2023 financial results, focusing on clinical developments, operational updates, and upcoming milestones. The company highlighted positive data from HBV and HPV programs, secured future funding, and planned Phase 1 clinical trials. Financially, Barinthus Bio's cash position decreased, revenue dropped significantly, and research and development expenses increased. The net loss for 2023 was $73.3 million.

Barinthus Biotherapeutics plc (NASDAQ: BRNS) expects to extend its cash runway from Q2 2025 to Q4 2025. The company anticipates multiple data readouts from clinical trials in 2024, focusing on hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection, prostate cancer programs, and the initiation of the first in human study for VTP-1000 in Celiac Disease. As of December 31, 2023, the company's cash and cash equivalents are expected to be $142 million, with approximately 38.6 million ordinary shares issued and outstanding.

Barinthus Biotherapeutics plc (NASDAQ: BRNS) receives funding from CEPI and the University of Oxford to fast-track the development of MERS vaccine candidate VTP-500